December 30, 2024 8:29am

Understanding that Q4/24 earnings are a-comin’

News: Precigen (PGEN +$0.10 or +14.43% to $0.8311) Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 <an AdenoVerse® gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus (HPV) 6 or HPV 11> for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Pre-open Indications: 6 Negative and 4 Positive Indications

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Friday’s night’s … RegMed Investors (RMi) Closing Bell: a wanted Santa Claus rally turned into coal drop … https://www.regmedinvestors.com/articles/13747

 

Monday; the pre-open Dow futures are DOWN -0.78% or (-339 points), the S&P futures are DOWN -0.94% or (-56 points) and the Nasdaq futures are DOWN -1.06% or (-229 points)

  • Stock futures were lower,
  • European markets traded in negative territory in its trading session of 2024,
  • Asia-Pacific markets traded mixed.

 

Henry’omics: We need to more certainty  to comprehend any movement in “our” universe of cell and gene therapy companies

Friday: The Dow closed DOWN -333.59 points or -0.77%, the S&P closed DOWN -66.75 points or -1.11% while the Nasdaq closed DOWN -298.33 points or -1.49%

  • Friday’s sector advance/decline line ended with a negative close at the close of 1 incliner, 31 decliners and 3 flats

The major averages are heading into the yearend shy of record levels, with the S&P 500 up +25% and the Dow +14% while the Nasdaq has gained more than 31%.

Economic Data Docket: This week ushers in a light period for economic data, with the market closed Wednesday in observance of New Years Day. Chicago PMI and pending homes sales data are due out Monday.

 

Q4/24: December = 1 holiday, 12 negative and 5 positive closes

  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

  • Mesoblast (MESO) closed down -$0.46 with a positive +$0.45 or +2.57% pre-open
  • Precigen (PGEN) closed down -$0.0124 with a positive +$0.10 or +14.43% pre-open indication
  • Regenxbio (RGNX) closed down -$0.45 with a positive +0.09 or +1.21% pre-open
  • Sage Therapeutics (SAGE) closed down -$0.19 with a positive +$0.25 or +4.51% aftermarket
  • Voyager Therapeutics (VYGR) closed down -$0.17 with a positive +$0.02 or +0.35% pre-open

Negative Indications:

  • Alnylam Pharmaceuticals (ALNY) closed down -$4.53 with a negative -$1.97 or -0.83% pre-open
  • Blueprint Medicine (BPMC) closed down -$2.22 with a negative -$0.21 or -0.23% pre-open
  • CRISPR Therapeutics (CRSP) closed down -$1.05 with a negative -$0.41 or -1.03% aftermarket
  • Lenz Therapeutics (LENZ) closed down -$0.69 with a negative -$1.17 or -3.74% pre-open
  • uniQure NV (QURE) closed down -$0.23 with a negative -$0.32 or -1.83% pre-open
  • Ultragenyx Pharmaceuticals (RARE) closed down -$0.40 with a negative -$0.81 or -1.87% pre-open

 

The BOTTOM LINE:  There are clear winners with mostly losers in December … and 2024.

  • Think about it; the biggest problem the cell and gene therapy sector has …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject to debt servicing firms!

 

I seem to be asking a question followed by a question …

  • Do we need to brace ourself for more economics and their down trending affect?
  • Is this market STILL “bubblicious” my concerns are macroeconomic and valuation

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.